Evotec Announces Progress
Evotec Announces Progress in Preclinical Neuroscience Partnership with Bristol Myers Squibb
HAMBURG, DE, October 27, 2025. Evotec SE announced that the Company has received a payment of US$ 25 m from Bristol Myers Squibb for scientific progress achieved within their strategic neuroscience partnership. The payment will advance further research and the partners' joint pipeline of programs aimed at tackling neurogenerative diseases.
Launched in 2016, the collaboration focuses on discovering and developing disease-modifying treatments for neurodegenerative diseases, where current treatment options remain limited. Since then, the companies have built a strong pipeline of innovative programs, including EVT8683, in-licensed by Bristol Myers Squibb in 2021 as BMS-986419, that has completed Phase 1 clinical trials. The partnership was extended in 2023 for an additional eight years, reflecting the shared commitment to bringing transformative treatments into the clinic.
Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "Patients living with neurodegenerative conditions urgently need therapies that go beyond the management of symptoms. This achievement increases the depth of our collaboration with Bristol Myers Squibb. Together, we are translating emerging disease biology into potential therapeutic opportunities, with the goal of providing meaningful new options for patients suffering from neurodegenerative diseases."
About Evotec SE
Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure - faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling.
With flexible partnering models tailored to our customers' needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility.
